Abciximab
Mycophenolic acid may increase the anticoagulant activities of Abciximab.
Acebutolol
Mycophenolic acid may decrease the antihypertensive activities of Acebutolol.
Aceclofenac
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aceclofenac.
Advertisement
Acemetacin
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acemetacin.
Acenocoumarol
Mycophenolic acid may increase the anticoagulant activities of Acenocoumarol.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mycophenolic acid.
Advertisement
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.
Aclarubicin
Mycophenolic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolic acid.
Advertisement
Alclometasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.
Aliskiren
Mycophenolic acid may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alminoprofen.
Alprenolol
Mycophenolic acid may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolic acid.
Aluminum
Aluminium can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum Hydroxide
Aluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
aluminum hydroxide, dried (USP)
Aluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum Magnesium Silicate
Almasilate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amcinonide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Amcinonide.
Amdinocillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amdinocillin resulting in a loss in efficacy.
Amdinocillin Pivoxil
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivmecillinam resulting in a loss in efficacy.
Amikacin
Mycophenolic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Mycophenolic acid may decrease the antihypertensive activities of Amiloride.
Amoxicillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amoxicillin resulting in a loss in efficacy.
Amoxicillin Anhydrous
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amoxicillin resulting in a loss in efficacy.
Ampicillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ampicillin resulting in a loss in efficacy.
Ampicillin (anhydrous)
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ampicillin resulting in a loss in efficacy.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Mycophenolic acid.
Ancrod
Mycophenolic acid may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Androstenedione.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Mycophenolic acid.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anthrax immune globulin human.
Antipyrine
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.
Antithrombin III
Mycophenolic acid may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Mycophenolic acid may increase the anticoagulant activities of Antithrombin III human.
Apazone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.
Apixaban
Mycophenolic acid may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apremilast.
Arbekacin
Mycophenolic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Mycophenolic acid may increase the anticoagulant activities of Ardeparin.
Argatroban
Mycophenolic acid may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Mycophenolic acid may increase the anticoagulant activities of Argatroban.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mycophenolic acid.
Atenolol
Mycophenolic acid may decrease the antihypertensive activities of Atenolol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.
azficel-T
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azficel-T.
Azidocillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azidocillin resulting in a loss in efficacy.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.
Azlocillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azlocillin resulting in a loss in efficacy.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Mycophenolic acid.
Bacampicillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Bacampicillin resulting in a loss in efficacy.
Balsalazide
Mycophenolic acid may increase the nephrotoxic activities of Balsalazide.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mycophenolic acid.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bacillus calmette-guerin substrain tice live antigen.
Becaplermin
Mycophenolic acid may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolic acid.
Benzydamine
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benzydamine.
Benzylpenicilloyl polylysine
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicilloyl Polylysine resulting in a loss in efficacy.
Betamethasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betamethasone.
Betaxolol
Mycophenolic acid may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Mycophenolic acid.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Mycophenolic acid.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Mycophenolic acid.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolic acid.
Bismuth Subcitrate
Bismuth Subcitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bisoprolol
Mycophenolic acid may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Mycophenolic acid may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Mycophenolic acid may decrease the antihypertensive activities of Bopindolol.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Mycophenolic acid.
Budesonide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Mycophenolic acid.
Bupranolol
Mycophenolic acid may decrease the antihypertensive activities of Bupranolol.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.
Calcium Carbonate
Calcium Carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CALCIUM CARBONATE, PRECIPITATED
Calcium Carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mycophenolic acid.
Captopril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Captopril.
Carbenicillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carbenicillin resulting in a loss in efficacy.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolic acid.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolic acid.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Mycophenolic acid.
Carteolol
Mycophenolic acid may decrease the antihypertensive activities of Carteolol.
Carvedilol
Mycophenolic acid may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Celecoxib.
Celiprolol
Mycophenolic acid may decrease the antihypertensive activities of Celiprolol.
Certoparin
Mycophenolic acid may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.
Chlorotrianisene
The serum concentration of Chlorotrianisene can be decreased when it is combined with Mycophenolic acid.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolic acid.
Cholestyramine Resin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Cholestyramine.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Choline magnesium trisalicylate.
Ciclesonide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cilazapril.
Cinoxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Cinoxacin.
Citric Acid
Mycophenolic acid may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Mycophenolic acid may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clodronic Acid.
Clofezone
The serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.
Clonixin
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clonixin.
Cloxacillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cloxacillin resulting in a loss in efficacy.
Colesevelam
The serum concentration of Mycophenolic acid can be decreased when it is combined with Colesevelam.
Colestipol
The serum concentration of Mycophenolic acid can be decreased when it is combined with Colestipol.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortisone acetate.
Curcumin
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Curcumin.
Cyclacillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mycophenolic acid.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.
Cyclosporine
The serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.
Dabigatran Etexilate
Mycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.
Dalteparin
Mycophenolic acid may increase the anticoagulant activities of Dalteparin.
Danaparoid
Mycophenolic acid may increase the anticoagulant activities of Danaparoid.
Daunorubicin
Mycophenolic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Deferasirox
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deflazacort.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.
Desirudin
Mycophenolic acid may increase the anticoagulant activities of Desirudin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Mycophenolic acid.
Desmopressin
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.
Desogestrel
The serum concentration of Desogestrel can be decreased when it is combined with Mycophenolic acid.
Desonide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone Pivalate.
Dexamethasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolic acid.
Dexlansoprazole
The serum concentration of Mycophenolic acid can be decreased when it is combined with Dexlansoprazole.
Dextran
Mycophenolic acid may increase the anticoagulant activities of Dextran.
Dextran 40
Mycophenolic acid may increase the anticoagulant activities of Dextran 40.
Dextran 70
Mycophenolic acid may increase the anticoagulant activities of Dextran 70.
Dextran 75
Mycophenolic acid may increase the anticoagulant activities of Dextran 75.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolic acid.
Dicloxacillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Dicloxacillin resulting in a loss in efficacy.
Dicumarol
Mycophenolic acid may increase the anticoagulant activities of Dicoumarol.
Dienestrol
The serum concentration of Dienestrol can be decreased when it is combined with Mycophenolic acid.
Dienogest
The serum concentration of Dienogest can be decreased when it is combined with Mycophenolic acid.
Diethylstilbestrol
The serum concentration of Diethylstilbestrol can be decreased when it is combined with Mycophenolic acid.
Diflorasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Mycophenolic acid.
Difluprednate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluprednate.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Mycophenolic acid.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Mycophenolic acid.
Dihydrostreptomycin
Mycophenolic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Mycophenolic acid.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolic acid.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolic acid.
Dipyrone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.
Doxorubicin
Mycophenolic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxorubicin Hydrochloride
Mycophenolic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Drospirenone
The serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.
Droxicam
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Droxicam.
Edetic Acid
Mycophenolic acid may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Mycophenolic acid may increase the anticoagulant activities of Edoxaban.
Enalapril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalaprilat.
Enoxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Enoxacin.
Enoxaparin
Mycophenolic acid may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Mycophenolic acid may increase the anticoagulant activities of Enoxaparin.
Epirubicin
Mycophenolic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.
Eplerenone
Mycophenolic acid may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.
Esmolol
Mycophenolic acid may decrease the antihypertensive activities of Esmolol.
Esomeprazole
The serum concentration of Mycophenolic acid can be decreased when it is combined with Esomeprazole.
Estradiol
The serum concentration of Estradiol can be decreased when it is combined with Mycophenolic acid.
Estramustine
The serum concentration of Estramustine can be decreased when it is combined with Mycophenolic acid.
Estrogens, Conjugated (USP)
The serum concentration of Conjugated estrogens can be decreased when it is combined with Mycophenolic acid.
Estrogens, Esterified (USP)
The serum concentration of Estrogens, esterified can be decreased when it is combined with Mycophenolic acid.
Estrone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mycophenolic acid.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mycophenolic acid.
Ethinyl Estradiol
The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mycophenolic acid.
Ethylenediaminetetraacetate
Mycophenolic acid may increase the anticoagulant activities of Edetic Acid.
Ethynodiol Diacetate
The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mycophenolic acid.
Etidronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etodolac.
Etofenamate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etofenamate.
Etonogestrel
The serum concentration of Etonogestrel can be decreased when it is combined with Mycophenolic acid.
Etoricoxib
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.
Evening primrose oil
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Evening primrose oil.
Felbinac
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Felbinac.
Fenbufen
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenbufen.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolic acid.
Ferulic Acid
Mycophenolic acid may increase the anticoagulant activities of Ferulic acid.
Fingolimod
Mycophenolic acid may increase the immunosuppressive activities of Fingolimod.
Fleroxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolic acid.
Floxacillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Flucloxacillin resulting in a loss in efficacy.
Fludrocortisone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fludrocortisone.
Fluindione
Mycophenolic acid may increase the anticoagulant activities of Fluindione.
Flumequine
The serum concentration of Mycophenolic acid can be decreased when it is combined with Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluorometholone.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mycophenolic acid.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone propionate.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolic acid.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolic acid.
Fondaparinux
Mycophenolic acid may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Mycophenolic acid may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fosinopril.
Framycetin
Mycophenolic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Mycophenolic acid.
Ganciclovir
The serum concentration of Ganciclovir can be increased when it is combined with Mycophenolic acid.
Gatifloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Gatifloxacin.
Gatifloxacin Anhydrous
The serum concentration of Mycophenolic acid can be decreased when it is combined with Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolic acid.
Gemifloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Gemifloxacin.
Gemifloxacin Mesylate
The serum concentration of Mycophenolic acid can be decreased when it is combined with Gemifloxacin.
Gentamicin
Mycophenolic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gestodene
The serum concentration of Gestodene can be decreased when it is combined with Mycophenolic acid.
Grepafloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.
Heparin
Mycophenolic acid may increase the anticoagulant activities of Heparin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hepatitis B Vaccine (Recombinant).
Hydralazine
Mycophenolic acid may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolic acid.
Hydrocortisone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolic acid.
Hydrotalcite
Hydrotalcite can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ibandronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuprofen.
Icatibant
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.
Idarubicin
Mycophenolic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.
Imidapril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.
Indobufen
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indobufen.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolic acid.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.
Isavuconazonium
The serum concentration of Mycophenolic acid can be increased when it is combined with Isavuconazonium.
Kanamycin
Mycophenolic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Mycophenolic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Kebuzone.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolic acid.
Labetalol
Mycophenolic acid may decrease the antihypertensive activities of Labetalol.
Lansoprazole
The serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Mycophenolic acid.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Mycophenolic acid.
Leflunomide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Leflunomide.
Lepirudin
Mycophenolic acid may increase the anticoagulant activities of Lepirudin.
Levobunolol
Mycophenolic acid may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.
Levofloxacin Anhydrous
The serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.
Levonorgestrel
The serum concentration of Levonorgestrel can be decreased when it is combined with Mycophenolic acid.
Limonene, (+)-
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with (4R)-limonene.
Lisinopril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.
Lornoxicam
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.
Loteprednol
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loteprednol.
Loxoprofen
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loxoprofen.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolic acid.
Lynestrenol
The serum concentration of Lynestrenol can be decreased when it is combined with Mycophenolic acid.
Magaldrate
Magaldrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Hydroxide
Magnesium hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Oxide
Magnesium oxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Salicylate
The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate.
Magnesium Sulfate
The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium sulfate.
Magnesium Trisilicate
Magnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolic acid.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.
Medronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m medronate.
Medroxyprogesterone Acetate
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.
Medrysone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mycophenolic acid.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Mycophenolic acid.
Mesalamine
Mycophenolic acid may increase the nephrotoxic activities of Mesalazine.
Mestranol
The serum concentration of Mestranol can be decreased when it is combined with Mycophenolic acid.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.
Methylprednisolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methylprednisolone.
Metipranolol
Mycophenolic acid may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.
Metoprolol
Mycophenolic acid may decrease the antihypertensive activities of Metoprolol.
Metrizamide
Mycophenolic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.
Metronidazole
The serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole.
Mezlocillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Mezlocillin resulting in a loss in efficacy.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolic acid.
Moexipril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolic acid.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.
Nabumetone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nabumetone.
Nadolol
Mycophenolic acid may decrease the antihypertensive activities of Nadolol.
Nadroparin
Mycophenolic acid may increase the anticoagulant activities of Nadroparin.
Nafcillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Nafcillin resulting in a loss in efficacy.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Mycophenolic acid.
Nalidixic Acid
The serum concentration of Mycophenolic acid can be decreased when it is combined with Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Mycophenolic acid.
Natalizumab
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.
Nebivolol
Mycophenolic acid may decrease the antihypertensive activities of Nebivolol.
Neomycin
Mycophenolic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Mycophenolic acid.
Netilmicin
Mycophenolic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Niflumic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.
Nimesulide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nimesulide.
Norelgestromin
The serum concentration of Norelgestromin can be decreased when it is combined with Mycophenolic acid.
Norfloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Norfloxacin.
Norgestimate
The serum concentration of Norgestimate can be decreased when it is combined with Mycophenolic acid.
Norgestrel
The serum concentration of Norgestrel can be decreased when it is combined with Mycophenolic acid.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Mycophenolic acid.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Evening primrose oil.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.
Olsalazine
Mycophenolic acid may increase the nephrotoxic activities of Olsalazine.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Mycophenolic acid is combined with Omacetaxine mepesuccinate.
Omeprazole
The serum concentration of Mycophenolic acid can be decreased when it is combined with Omeprazole.
Ouabain
Ouabain may decrease the cardiotoxic activities of Mycophenolic acid.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mycophenolic acid.
Oxacillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Oxacillin resulting in a loss in efficacy.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Mycophenolic acid.
Oxprenolol
Mycophenolic acid may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.
Pamidronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.
Pantoprazole
The serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.
Paramethasone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parecoxib.
Paromomycin
Mycophenolic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Parthenolide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parthenolide.
Pefloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Pefloxacin.
Penbutolol
Mycophenolic acid may decrease the antihypertensive activities of Penbutolol.
Penicillin G
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicillin resulting in a loss in efficacy.
penicillin G benzathine
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzathine benzylpenicillin resulting in a loss in efficacy.
penicillin G procaine
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Procaine benzylpenicillin resulting in a loss in efficacy.
Penicillin V
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Phenoxymethylpenicillin resulting in a loss in efficacy.
Pentaerythritol Tetranitrate
Mycophenolic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Mycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Perindopril.
Phenindione
Mycophenolic acid may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Mycophenolic acid may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mycophenolic acid.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.
Pindolol
Mycophenolic acid may decrease the antihypertensive activities of Pindolol.
Piperacillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy.
Piperacillin Anhydrous
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy.
Pirarubicin
Mycophenolic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Mycophenolic acid.
Pirfenidone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.
Pivampicillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivampicillin resulting in a loss in efficacy.
Plicamycin
Mycophenolic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolic acid.
Practolol
Mycophenolic acid may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Mycophenolic acid.
Prasterone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pregnenolone.
Probenecid
The serum concentration of Mycophenolic acid can be increased when it is combined with Probenecid.
Propicillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Propicillin resulting in a loss in efficacy.
Propranolol
Mycophenolic acid may decrease the antihypertensive activities of Propranolol.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Mycophenolic acid.
protein C, human
Mycophenolic acid may increase the anticoagulant activities of Protein C.
protein S, human
Mycophenolic acid may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Mycophenolic acid may increase the anticoagulant activities of Protocatechualdehyde.
Quinapril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Quinapril.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolic acid.
Rabeprazole
The serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mycophenolic acid.
Ramipril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ramipril.
Rescinnamine
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.
Reviparin
Mycophenolic acid may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Mycophenolic acid may increase the anticoagulant activities of Reviparin.
Rifampin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Rifampicin.
Rimexolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.
Rivaroxaban
Mycophenolic acid may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rofecoxib.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Mycophenolic acid.
Rosoxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Rosoxacin.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rubella virus vaccine.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Mycophenolic acid.
Salicylamide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Mycophenolic acid.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salmonella typhi ty21a live antigen.
Salsalate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Mycophenolic acid.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Serrapeptase.
Sevelamer
The serum concentration of Mycophenolic acid can be decreased when it is combined with Sevelamer.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolic acid.
Sisomicin
Mycophenolic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Bicarbonate
Sodium bicarbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Mycophenolic acid.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Mycophenolic acid.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Mycophenolic acid.
Sotalol
Mycophenolic acid may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Sparfloxacin.
Spectinomycin
Mycophenolic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.
Spirapril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Spirapril.
Spironolactone
Mycophenolic acid may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Mycophenolic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin
Mycophenolic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.
Sulbactam
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sulbactam resulting in a loss in efficacy.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mycophenolic acid.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolic acid.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Mycophenolic acid.
synthetic conjugated estrogens, A
The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Mycophenolic acid.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Mycophenolic acid.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Mycophenolic acid.
Talinolol
Mycophenolic acid may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolic acid.
Tazobactam
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Tazobactam resulting in a loss in efficacy.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.
Temafloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolic acid.
Teriflunomide
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.
Ticarcillin
The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ticarcillin resulting in a loss in efficacy.
Tiludronate
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiludronic acid.
Timolol
Mycophenolic acid may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Mycophenolic acid may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tixocortol.
Tobramycin
Mycophenolic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tofacitinib
Mycophenolic acid may increase the immunosuppressive activities of Tofacitinib.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tolfenamic Acid.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolic acid.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Mycophenolic acid.
Trandolapril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tranilast.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Mycophenolic acid.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.
Triamcinolone
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triamcinolone.
Triamterene
Mycophenolic acid may decrease the antihypertensive activities of Triamterene.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolic acid.
Tromethamine
Tromethamine can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trovafloxacin
The serum concentration of Mycophenolic acid can be decreased when it is combined with Trovafloxacin.
Troxerutin
Mycophenolic acid may increase the anticoagulant activities of Troxerutin.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salmonella typhi ty2 vi polysaccharide antigen.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolic acid.
Valacyclovir
The serum concentration of Mycophenolic acid can be increased when it is combined with Valaciclovir.
Valdecoxib
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Valdecoxib.
Valganciclovir
The serum concentration of Valganciclovir can be increased when it is combined with Mycophenolic acid.
Valrubicin
Mycophenolic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Mycophenolic acid.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Varicella Zoster Vaccine (Live/Attenuated).
Warfarin
Mycophenolic acid may increase the anticoagulant activities of Warfarin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Yellow Fever Vaccine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Mycophenolic acid.
Zofenopril
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.
